Classification  ||| S:0 E:15 ||| JJ
criteria  ||| S:15 E:24 ||| NNS
for  ||| S:24 E:28 ||| IN
rheumatoid  ||| S:28 E:39 ||| JJ
arthritis  ||| S:39 E:49 ||| NN
and  ||| S:49 E:53 ||| CC
ankylosing  ||| S:53 E:64 ||| NNS
spondylitis  ||| S:64 E:76 ||| VBP
The  ||| S:76 E:80 ||| DT
history  ||| S:80 E:88 ||| NN
of  ||| S:88 E:91 ||| IN
classification  ||| S:91 E:106 ||| NN
and  ||| S:106 E:110 ||| CC
diagnostic  ||| S:110 E:121 ||| JJ
criteria  ||| S:121 E:130 ||| NNS
for  ||| S:130 E:134 ||| IN
rheumatoid  ||| S:134 E:145 ||| JJ
arthritis  ||| S:145 E:155 ||| NN
( ||| S:155 E:156 ||| -LRB-
RA ||| S:156 E:158 ||| NNP
)  ||| S:158 E:160 ||| -RRB-
and  ||| S:160 E:164 ||| CC
ankylosing  ||| S:164 E:175 ||| JJ
spondylitis  ||| S:175 E:187 ||| NNS
( ||| S:187 E:188 ||| -LRB-
AS ||| S:188 E:190 ||| NNP
)  ||| S:190 E:192 ||| -RRB-
is  ||| S:192 E:195 ||| VBZ
similar  ||| S:195 E:203 ||| JJ
and  ||| S:203 E:207 ||| CC
different ||| S:207 E:216 ||| JJ
.  ||| S:216 E:218 ||| .
Important  ||| S:218 E:228 ||| JJ
criteria  ||| S:228 E:237 ||| NNS
sets  ||| S:237 E:242 ||| NNS
have  ||| S:242 E:247 ||| VBP
been  ||| S:247 E:252 ||| VBN
published  ||| S:252 E:262 ||| VBN
for  ||| S:262 E:266 ||| IN
both  ||| S:266 E:271 ||| DT
disease  ||| S:271 E:279 ||| NN
in  ||| S:279 E:282 ||| IN
the  ||| S:282 E:286 ||| DT
mid  ||| S:286 E:290 ||| JJ
eighties ||| S:290 E:298 ||| NN
,  ||| S:298 E:300 ||| ,
for  ||| S:300 E:304 ||| IN
AS  ||| S:304 E:307 ||| NNP
in  ||| S:307 E:310 ||| IN
1984  ||| S:310 E:315 ||| CD
and  ||| S:315 E:319 ||| CC
for  ||| S:319 E:323 ||| IN
RA  ||| S:323 E:326 ||| NNP
in  ||| S:326 E:329 ||| IN
1987 ||| S:329 E:333 ||| CD
.  ||| S:333 E:335 ||| .
The  ||| S:335 E:339 ||| DT
leading  ||| S:339 E:347 ||| JJ
clinical  ||| S:347 E:356 ||| JJ
symptoms ||| S:356 E:364 ||| NNS
,  ||| S:364 E:366 ||| ,
inflammatory  ||| S:366 E:379 ||| JJ
back  ||| S:379 E:384 ||| JJ
pain  ||| S:384 E:389 ||| NN
( ||| S:389 E:390 ||| -LRB-
IBP ||| S:390 E:393 ||| NNP
)  ||| S:393 E:395 ||| -RRB-
in  ||| S:395 E:398 ||| IN
AS  ||| S:398 E:401 ||| NNP
and  ||| S:401 E:405 ||| CC
the  ||| S:405 E:409 ||| DT
predominant  ||| S:409 E:421 ||| JJ
polyarticular  ||| S:421 E:435 ||| JJ
symmetric  ||| S:435 E:445 ||| JJ
involvement  ||| S:445 E:457 ||| NN
of  ||| S:457 E:460 ||| IN
the  ||| S:460 E:464 ||| DT
hands  ||| S:464 E:470 ||| NNS
in  ||| S:470 E:473 ||| IN
RA  ||| S:473 E:476 ||| NNP
were ||| S:476 E:480 ||| VBD
,  ||| S:480 E:482 ||| ,
of  ||| S:482 E:485 ||| IN
course ||| S:485 E:491 ||| NN
,  ||| S:491 E:493 ||| ,
central ||| S:493 E:500 ||| JJ
,  ||| S:500 E:502 ||| ,
and  ||| S:502 E:506 ||| CC
so  ||| S:506 E:509 ||| RB
was  ||| S:509 E:513 ||| VBD
morning  ||| S:513 E:521 ||| NN
stiffness  ||| S:521 E:531 ||| NN
as  ||| S:531 E:534 ||| IN
a  ||| S:534 E:536 ||| DT
major  ||| S:536 E:542 ||| JJ
clinical  ||| S:542 E:551 ||| JJ
sign  ||| S:551 E:556 ||| NN
of  ||| S:556 E:559 ||| IN
an  ||| S:559 E:562 ||| DT
inflammatory  ||| S:562 E:575 ||| JJ
disease  ||| S:575 E:583 ||| NN
state ||| S:583 E:588 ||| NN
.  ||| S:588 E:590 ||| .
In  ||| S:590 E:593 ||| IN
RA ||| S:593 E:595 ||| NNP
,  ||| S:595 E:597 ||| ,
there  ||| S:597 E:603 ||| EX
was  ||| S:603 E:607 ||| VBD
more  ||| S:607 E:612 ||| JJR
focus  ||| S:612 E:618 ||| NN
on  ||| S:618 E:621 ||| IN
laboratory  ||| S:621 E:632 ||| NN
parameters  ||| S:632 E:643 ||| NNS
( ||| S:643 E:644 ||| -LRB-
rheumatoid  ||| S:644 E:655 ||| JJ
factor ||| S:655 E:661 ||| NN
) ||| S:661 E:662 ||| -RRB-
,  ||| S:662 E:664 ||| ,
while  ||| S:664 E:670 ||| IN
this  ||| S:670 E:675 ||| DT
could  ||| S:675 E:681 ||| MD
have  ||| S:681 E:686 ||| VB
been  ||| S:686 E:691 ||| VBN
the  ||| S:691 E:695 ||| DT
case  ||| S:695 E:700 ||| NN
also  ||| S:700 E:705 ||| RB
in  ||| S:705 E:708 ||| IN
AS  ||| S:708 E:711 ||| NNP
( ||| S:711 E:712 ||| -LRB-
HLA  ||| S:712 E:716 ||| NNP
B27 ||| S:716 E:719 ||| NNP
)  ||| S:719 E:721 ||| -RRB-
but  ||| S:721 E:725 ||| CC
this  ||| S:725 E:730 ||| DT
was  ||| S:730 E:734 ||| VBD
not  ||| S:734 E:738 ||| RB
recognized  ||| S:738 E:749 ||| VBN
at  ||| S:749 E:752 ||| IN
this  ||| S:752 E:757 ||| DT
point  ||| S:757 E:763 ||| NN
in  ||| S:763 E:766 ||| IN
time ||| S:766 E:770 ||| NN
.  ||| S:770 E:772 ||| .
In  ||| S:772 E:775 ||| IN
contrast ||| S:775 E:783 ||| NN
,  ||| S:783 E:785 ||| ,
imaging  ||| S:785 E:793 ||| NN
has  ||| S:793 E:797 ||| VBZ
played  ||| S:797 E:804 ||| VBN
a  ||| S:804 E:806 ||| DT
more  ||| S:806 E:811 ||| RBR
important  ||| S:811 E:821 ||| JJ
role  ||| S:821 E:826 ||| NN
in  ||| S:826 E:829 ||| IN
AS  ||| S:829 E:832 ||| NNP
-  ||| S:832 E:834 ||| :
especially  ||| S:834 E:845 ||| RB
because  ||| S:845 E:853 ||| IN
the  ||| S:853 E:857 ||| DT
sacroiliac  ||| S:857 E:868 ||| JJ
joints  ||| S:868 E:875 ||| NNS
are  ||| S:875 E:879 ||| VBP
involved  ||| S:879 E:888 ||| VBN
in  ||| S:888 E:891 ||| IN
the  ||| S:891 E:895 ||| DT
vast  ||| S:895 E:900 ||| JJ
majority  ||| S:900 E:909 ||| NN
of  ||| S:909 E:912 ||| IN
AS  ||| S:912 E:915 ||| NNP
patients ||| S:915 E:923 ||| NNS
,  ||| S:923 E:925 ||| ,
while  ||| S:925 E:931 ||| IN
in  ||| S:931 E:934 ||| IN
RA  ||| S:934 E:937 ||| NNP
radiographic  ||| S:937 E:950 ||| NN
changes  ||| S:950 E:958 ||| NNS
of  ||| S:958 E:961 ||| IN
the  ||| S:961 E:965 ||| DT
joints  ||| S:965 E:972 ||| NN
of  ||| S:972 E:975 ||| IN
hands  ||| S:975 E:981 ||| NNS
and  ||| S:981 E:985 ||| CC
feet  ||| S:985 E:990 ||| NNS
may  ||| S:990 E:994 ||| MD
contribute  ||| S:994 E:1005 ||| VB
to  ||| S:1005 E:1008 ||| TO
the  ||| S:1008 E:1012 ||| DT
diagnosis ||| S:1012 E:1021 ||| NN
.  ||| S:1021 E:1023 ||| .
However ||| S:1023 E:1030 ||| RB
,  ||| S:1030 E:1032 ||| ,
in  ||| S:1032 E:1035 ||| IN
both  ||| S:1035 E:1040 ||| DT
diseases ||| S:1040 E:1048 ||| NNS
,  ||| S:1048 E:1050 ||| ,
early  ||| S:1050 E:1056 ||| RB
structural  ||| S:1056 E:1067 ||| JJ
changes  ||| S:1067 E:1075 ||| NNS
visualized  ||| S:1075 E:1086 ||| VBN
by  ||| S:1086 E:1089 ||| IN
conventional  ||| S:1089 E:1102 ||| JJ
radiography  ||| S:1102 E:1114 ||| NNS
rather  ||| S:1114 E:1121 ||| RB
have  ||| S:1121 E:1126 ||| VB
prognostic  ||| S:1126 E:1137 ||| JJ
impact  ||| S:1137 E:1144 ||| NN
since  ||| S:1144 E:1150 ||| IN
these  ||| S:1150 E:1156 ||| DT
patients  ||| S:1156 E:1165 ||| NNS
are  ||| S:1165 E:1169 ||| VBP
much  ||| S:1169 E:1174 ||| RB
more  ||| S:1174 E:1179 ||| RBR
likely  ||| S:1179 E:1186 ||| JJ
to  ||| S:1186 E:1189 ||| TO
progress  ||| S:1189 E:1198 ||| VB
in  ||| S:1198 E:1201 ||| IN
comparison  ||| S:1201 E:1212 ||| NN
to  ||| S:1212 E:1215 ||| TO
others  ||| S:1215 E:1222 ||| NNS
who  ||| S:1222 E:1226 ||| WP
do  ||| S:1226 E:1229 ||| VBP
not  ||| S:1229 E:1233 ||| RB
have  ||| S:1233 E:1238 ||| VB
cartilage  ||| S:1238 E:1248 ||| NN
and  ||| S:1248 E:1252 ||| CC
joint  ||| S:1252 E:1258 ||| JJ
damage  ||| S:1258 E:1265 ||| NN
early  ||| S:1265 E:1271 ||| RB
in  ||| S:1271 E:1274 ||| IN
the  ||| S:1274 E:1278 ||| DT
course  ||| S:1278 E:1285 ||| NN
of  ||| S:1285 E:1288 ||| IN
the  ||| S:1288 E:1292 ||| DT
disease ||| S:1292 E:1299 ||| NN
.  ||| S:1299 E:1301 ||| .
Further  ||| S:1301 E:1309 ||| JJ
developments  ||| S:1309 E:1322 ||| NNS
of  ||| S:1322 E:1325 ||| IN
criteria  ||| S:1325 E:1334 ||| NNS
for  ||| S:1334 E:1338 ||| IN
AS  ||| S:1338 E:1341 ||| NNP
have  ||| S:1341 E:1346 ||| VBP
broadened  ||| S:1346 E:1356 ||| VBN
the  ||| S:1356 E:1360 ||| DT
spectrum  ||| S:1360 E:1369 ||| NN
of  ||| S:1369 E:1372 ||| IN
AS  ||| S:1372 E:1375 ||| NNP
to  ||| S:1375 E:1378 ||| TO
spondyloarthritis  ||| S:1378 E:1396 ||| VB
( ||| S:1396 E:1397 ||| -LRB-
SpA ||| S:1397 E:1400 ||| NNP
)  ||| S:1400 E:1402 ||| -RRB-
and  ||| S:1402 E:1406 ||| CC
axial  ||| S:1406 E:1412 ||| JJ
SpA  ||| S:1412 E:1416 ||| NN
which  ||| S:1416 E:1422 ||| WDT
covers  ||| S:1422 E:1429 ||| VBZ
most  ||| S:1429 E:1434 ||| RBS
early  ||| S:1434 E:1440 ||| JJ
forms ||| S:1440 E:1445 ||| NNS
.  ||| S:1445 E:1447 ||| .
The  ||| S:1447 E:1451 ||| DT
leading  ||| S:1451 E:1459 ||| JJ
clinical  ||| S:1459 E:1468 ||| JJ
symptom  ||| S:1468 E:1476 ||| NN
is  ||| S:1476 E:1479 ||| VBZ
chronic  ||| S:1479 E:1487 ||| VBN
back  ||| S:1487 E:1492 ||| RP
pain  ||| S:1492 E:1497 ||| NN
in  ||| S:1497 E:1500 ||| IN
young  ||| S:1500 E:1506 ||| JJ
adults  ||| S:1506 E:1513 ||| NNS
and  ||| S:1513 E:1517 ||| CC
IBP ||| S:1517 E:1520 ||| NNP
.  ||| S:1520 E:1522 ||| .
New  ||| S:1522 E:1526 ||| JJ
criteria  ||| S:1526 E:1535 ||| NNS
for  ||| S:1535 E:1539 ||| IN
RA  ||| S:1539 E:1542 ||| NNP
which  ||| S:1542 E:1548 ||| WDT
include  ||| S:1548 E:1556 ||| VBP
more  ||| S:1556 E:1561 ||| JJR
patients  ||| S:1561 E:1570 ||| NNS
with  ||| S:1570 E:1575 ||| IN
early  ||| S:1575 E:1581 ||| JJ
disease  ||| S:1581 E:1589 ||| NN
and  ||| S:1589 E:1593 ||| CC
anti-CCP  ||| S:1593 E:1602 ||| JJ
antibodies  ||| S:1602 E:1613 ||| NNS
as  ||| S:1613 E:1616 ||| IN
new  ||| S:1616 E:1620 ||| JJ
markers  ||| S:1620 E:1628 ||| NNS
are  ||| S:1628 E:1632 ||| VBP
being  ||| S:1632 E:1638 ||| VBG
developed ||| S:1638 E:1647 ||| VBN
.  ||| S:1647 E:1649 ||| .
This  ||| S:1649 E:1654 ||| DT
is  ||| S:1654 E:1657 ||| VBZ
important  ||| S:1657 E:1667 ||| JJ
since  ||| S:1667 E:1673 ||| IN
early  ||| S:1673 E:1679 ||| JJ
treatment  ||| S:1679 E:1689 ||| NN
strategies  ||| S:1689 E:1700 ||| NNS
are  ||| S:1700 E:1704 ||| VBP
increasingly  ||| S:1704 E:1717 ||| RB
and  ||| S:1717 E:1721 ||| CC
successfully  ||| S:1721 E:1734 ||| RB
used  ||| S:1734 E:1739 ||| VBN
to  ||| S:1739 E:1742 ||| TO
treat  ||| S:1742 E:1748 ||| VB
inflammatory  ||| S:1748 E:1761 ||| JJ
diseases  ||| S:1761 E:1770 ||| NNS
more  ||| S:1770 E:1775 ||| RBR
efficiently ||| S:1775 E:1786 ||| RB
.  ||| S:1786 E:1788 ||| .
